88091-36-5

Usage

Common uses

Synthesis of pharmaceuticals, agrochemicals, and other organic compounds

Potential applications

Medicine, chemistry, materials science, biological and pharmacological activities

Role in organic synthesis

Important building block

Utilized in

Preparation of diverse chemical products

Upstream product

• 94128-94-6 (1-Phenyl-1H-imidazol-4-yl)-methanol 
• 85102-89-2 N¹-(4-Nitrophenyl)-4-hydroxymethylimidazole 
• 591-50-4 iodobenzene 
• 3034-50-2 5-imidazolecarboxaldehyde 
• 108-86-1 bromobenzene 
• 3034-50-2 4⁽⁵⁾formylimidazole 
• 94128-93-5 1-(p-aminophenyl)-4-hydroxymethylimidazole 

Downstream Products

• 94128-87-7 C₁₁H₁₁N₅S 
• 94128-87-7 C₁₁H₁₁N₅S 
• 932974-43-1 1-phenyl-1H-imidazole-4-carbonitrile 
• 92642-75-6 1-phenyl-4-[(hydroxyimino)methyl]-3-methylimidazolium iodide 

Relevant academic research and scientific papers

Biomimetic non-heme iron-catalyzed epoxidation of challenging terminal alkenes using aqueous H2O2 as an environmentally friendly oxidant

Catalysis mediated by iron complexes is emerging as an eco-friendly and inexpensive option in comparison to traditional metal catalysis. The epoxidation of alkenes constitutes an attractive application of iron(III) catalysis, in which terminal olefins are challenging substrates. Herein, we describe our study on the design of biomimetic non-heme ligands for the in situ generation of iron(III) complexes and their evaluation as potential catalysts in epoxidation of terminal olefins. Since it is well-known that active sites of oxidases might involve imidazole fragment of histidine, various simple imidazole derivatives (seven compounds) were initially evaluated in order to find the best reaction conditions and to develop, subsequently, more elaborated amino acid-derived peptide-like chiral ligands (10 derivatives) for enantioselective epoxidations.

ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES

A family of phosphorescent emitter compounds containing a carbene ligand LA selected from the group consisting of: is disclosed. These compounds enhance the performance of OLEDs when incorporated therein.

Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof

γ-Hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamide compounds are inhibitors of HIV protease and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. These compounds are effective against HIV viral mutants which are resistant to HIV protease inhibitors currently used for treating AIDS and HIV infection.